Amgen Inc. reports developments across its biotechnology medicines business, including discovery, development, manufacturing and delivery of human therapeutics. Company updates center on a portfolio and pipeline spanning cancer, inflammatory conditions, rare diseases, heart disease, obesity and obesity-related conditions, with named products and programs such as TEPEZZA, Repatha and IMDELLTRA appearing in clinical and commercial announcements.
Recurring news also covers quarterly financial results, non-GAAP performance measures, manufacturing network investments, supply-chain capacity, research collaborations, medical and investor conference presentations, and executive or organizational changes tied to the integration of biology, technology, artificial intelligence and data across Amgen's operations.
Amgen (NASDAQ:AMGN) reported strong Q2 2025 financial results with total revenues increasing 9% to $9.2 billion. Product sales grew 9%, driven by 13% volume growth, partially offset by 3% lower net selling price. GAAP EPS increased 92% to $2.65, while non-GAAP EPS rose 21% to $6.02.
Key highlights include fifteen products achieving double-digit sales growth, notably Repatha (+31%), EVENITY (+32%), UPLIZNA (+91%), and TEZSPIRE (+46%). The company generated $1.9 billion in free cash flow and maintained its 2025 revenue guidance of $35.0-36.0 billion.
However, some established products faced challenges, with Enbrel sales declining 34% and Prolia/XGEVA expecting sales erosion due to biosimilar competition in H2 2025.
Amgen (NASDAQ:AMGN) has announced its quarterly dividend payment for Q3 2025. The company's Board of Directors has declared a dividend of $2.38 per share. The dividend will be distributed on September 12, 2025, to stockholders who are on record as of the market close on August 22, 2025.
Amgen (NASDAQ:AMGN) has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, after U.S. market close. The company will host a conference call at 4:30 p.m. ET featuring CEO Robert A. Bradway and senior management.
The event will be accessible via webcast on www.amgen.com under the Investors section, with replay available for at least 90 days following the presentation.
Amgen (NASDAQ:AMGN) announced positive topline results from its Phase 3 FORTITUDE-101 clinical trial for bemarituzumab in gastric cancer treatment. The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in overall survival (OS) when combining bemarituzumab with chemotherapy compared to placebo plus chemotherapy.
The study focused on patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and non-HER2 positive status. This breakthrough is particularly significant given that gastric cancer is the fifth leading cause of cancer-related death worldwide, with nearly one million new cases and over 650,000 deaths annually.
The most common treatment-emergent adverse events included reduced visual acuity, punctate keratitis, anemia, neutropenia, nausea, corneal epithelium defect, and dry eye. Notably, ocular events occurred with greater frequency and severity in the bemarituzumab arm compared to the Phase 2 experience. A separate Phase 3 study combining bemarituzumab with chemotherapy and nivolumab is ongoing, with results expected in H2 2025.